DNA Sciences’ recent staff changes suggest a directional shift from traditional genomics to developing and commercializing diagnostic and drug-discovery products. The company fired chairman and CEO Hugh Reinhoff, whose position was assumed by former chief business officer Steve Lehrer. Suffering from what observers noted as a high cash burn rate, the company will also lay off roughly half of its 175-member workforce, according to a spokeswoman, who adds that most of the personnel cuts would be at the Fremont, Calif., headquarters.
“We will continue to pursue the commercial opportunities through our DNA Sciences Laboratories business, and the pharmaco-genetic research activities that the company undertakes,” the spokeswoman says. In fact, DNA Sciences Laboratories, formerly known as PPGx, is expected to increase its staff size by 25 percent within the next few months. The division focuses on genotyping, target validation, and SNP discovery.
— Kirell Lakhman